Glycoprotein IIb/IIIa inhibitor associated severe thrombocytopenia in patients with coronary artery disease: Clinical course and outcomes

Platelets

Volumn 23, Issue 3, 2012, Pages 224-228

  Viswanathan, Girish ^a   Kidambi, Ananth ^b   Nelson, Adam ^c   Mayurathan, Gnanamoorthy ^d   Hardy, John ^d   Kesteven, Patrick ^d   Zaman, Azfar ^a,d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Coronary artery disease; Glycoprotein IIb IIIa inhibitors; Platelets; Severe thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION;

AGED; CORONARY ARTERY DISEASE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; SURVIVAL RATE; THROMBOCYTOPENIA; TIME FACTORS;

EID: 84859752689     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2011.604804     Document Type: Article

References (26)

1. Wang TY, Ou FS, Roe MT, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation 2009;119:2454-2462.
2. Matthai Jr WH. Thrombocytopenia in cardiovascular patients: Diagnosis and management. Chest 2005;127:46S-52S.
3. Cornet AD, Klein LJ, Groeneveld AB. Coronary stent occlusion after platelet transfusion: A case series. J Invasive Cardiol 2007;19:E297-E299.
4. Vamvakas EC. Platelet transfusion and adverse outcomes. Lancet 2004;364:1736-1738.
5. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
6. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE, Kandzari DE, Topol EJ, Califf RM. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003;92:651-655.
7. Labinaz M, Ho C, Banerjee S, Martin J, Chen S, Mensinkai S. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol 2007;23:963-970.
8. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071-2076.
9. Huxtable LM, Tafreshi MJ, Rakkar AN. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006;97:426-429.
10. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109:2203-2206.
11. Coller BS. Anti-GPIIb/IIIa drugs: Current strategies and future directions. Thromb Haemost 2001;86:427-443.
12. Overgaard CB, Ivanov J, Seidelin PH, Todorov M, Mackie K, Dzavik V. Thrombocytopenia at baseline is a predictor of inhospital mortality in patients undergoing percutaneous coronary intervention. Am Heart J 2008;156:120-124.
13. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P. Thrombolysis in Myocardial Infarction (TIMI) trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-154.
14. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: A nuisance in both bare metal and drug-eluting stents. Circulation 2007;115:1433-1439, discussion 1439.
15. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2004:CD004269. pp. 1-39.
16. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007;357:580-587.
17. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation. 2004;109:2203-2206.
18. Kereiakes DJ, Berkowitz SD, Lincoff AM, Tcheng JE, Wolski K, Achenbach R, Melsheimer R, Anderson K, Califf RM, Topol EJ. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000;140:74-80.
19. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999;340:409-417.
20. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-1562.
21. Chun R, Orser BA, Madan M. Platelet glycoprotein IIb/IIIa inhibitors: Overview and implications for the anesthesiologist. Anesth Analg 2002;95:879-888.
22. Giugliano RP. Drug-induced thrombocytopenia: Is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors? J Thromb Thrombolysis 1998 5 191-202.
23. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999;6:437-441.
24. Said SM, Hahn J, Schleyer E, Muller M, Fiedler GM, Buerke M, Prondzinsky R. Glycoprotein IIb/IIIa inhibitorinduced thrombocytopenia: Diagnosis and treatment. Clin Res Cardiol 2007;96:61-69.
25. Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: Diagnosis and management update. Postgrad Med J 2007;83:575-582.
26. Warkentin TE, Crowther MA. Adverse prognostic significance of thrombocytopenia in acute coronary syndrome: Can anything be done about it? Circulation 2009 119 2420-2422.